TBCK Inhibitors
TBCK (TBC1 domain-containing kinase) inhibitors are a class of chemical compounds that primarily target the TBCK protein, a member of the TBC (Tre-2/Bub2/Cdc16) domain-containing kinase family. These inhibitors are designed to modulate the activity of TBCK by interfering with its kinase function, which plays a crucial role in various cellular processes. TBCK is a serine/threonine kinase involved in the regulation of intracellular signaling pathways and cellular homeostasis. It is characterized by the presence of a TBC domain, which is essential for its catalytic activity. TBCK inhibitors are specifically designed to interact with the TBC domain of the TBCK protein, disrupting its kinase activity and thereby influencing downstream cellular processes.
The inhibition of TBCK has garnered significant interest in the field of cellular and molecular biology due to its implications in various physiological and pathological processes. By selectively targeting TBCK, these inhibitors have the capacity to impact intracellular signaling cascades, cellular trafficking, and the regulation of key cellular events. Researchers are actively exploring the diverse roles of TBCK in cellular biology, and the development of TBCK inhibitors has provided a valuable tool for dissecting these functions and understanding the underlying mechanisms.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $80.00 $212.00 $408.00 | 48 | |
SB431542 inhibits TBCK by targeting the TGF-β signaling pathway, specifically blocking the activation of TGF-β type I receptors (ALK4, ALK5, ALK7). It prevents the phosphorylation of SMAD2/3, thereby attenuating downstream signaling. | ||||||
LY2157299 | 700874-72-2 | sc-391123 sc-391123A | 5 mg 10 mg | $209.00 $352.00 | 3 | |
LY2157299 is a selective TGF-β receptor kinase inhibitor. It disrupts TGF-β signaling by inhibiting the activation of TGF-β type I receptors, leading to reduced phosphorylation of SMAD2/3 and inhibition of downstream effects. | ||||||
TGF-β RI Kinase Inhibitor V | 627536-09-8 | sc-203294 | 2 mg | $86.00 | 3 | |
SD-208 inhibits the TGF-β/SMAD signaling pathway by targeting the TGF-β type I receptor, preventing its activation and subsequent phosphorylation of SMAD2/This action attenuates TGF-β-mediated cellular responses. | ||||||
A 83-01 | 909910-43-6 | sc-203791 sc-203791A | 10 mg 50 mg | $198.00 $650.00 | 16 | |
A8301 is a potent inhibitor of the TGF-β/ALK5 signaling pathway. It impedes the phosphorylation of SMAD2/3 by blocking the activation of ALK5, thereby inhibiting downstream TGF-β effects. | ||||||
LY2109761 | 700874-71-1 | sc-396262 sc-396262A | 1 mg 5 mg | $87.00 $270.00 | 9 | |
LY2109761 is a dual inhibitor of TGF-β type I and type II receptors. It disrupts TGF-β signaling by inhibiting receptor activation, leading to decreased SMAD2/3 phosphorylation and TGF-β response inhibition. | ||||||
ALK5 Inhibitor II | 446859-33-2 | sc-221234 sc-221234A sc-221234B sc-221234C sc-221234D sc-221234E sc-221234F | 1 mg 5 mg 10 mg 50 mg 100 mg 500 mg 1 g | $75.00 $150.00 $215.00 $650.00 $1224.00 $4296.00 $7818.00 | 8 | |
RepSox targets the ALK5 kinase and inhibits its activity, thereby disrupting the TGF-β/SMAD signaling pathway. It prevents the phosphorylation of SMAD2/3 and attenuates TGF-β-mediated cellular responses. | ||||||
EW-7197 | 1352608-82-2 | sc-507465 | 5 mg | $345.00 | ||
EW-7197 is a selective ALK5 inhibitor that impedes the TGF-β signaling pathway. It inhibits ALK5 activation, reducing SMAD2/3 phosphorylation and attenuating TGF-β-induced effects. | ||||||
GW788388 | 452342-67-5 | sc-363544 sc-363544A | 5 mg 25 mg | $95.00 $384.00 | ||
GW788388 selectively inhibits ALK5 and ALK4, key receptors in the TGF-β pathway. It disrupts TGF-β signaling by preventing receptor activation and downstream SMAD2/3 phosphorylation. | ||||||
TGF-β RI Kinase Inhibitor VIII | 356559-20-1 | sc-203295 | 2 mg | $100.00 | 2 | |
SB525334 targets the TGF-β type I receptor ALK5, inhibiting its activation. This leads to reduced phosphorylation of SMAD2/3 and attenuation of TGF-β-mediated cellular responses. | ||||||
ITD 1 | 1099644-42-4 | sc-507349 | 10 mg | $220.00 | ||
ITD-1 is a TGF-β receptor type I kinase inhibitor that interferes with the TGF-β signaling pathway by blocking ALK5 activation. This results in decreased SMAD2/3 phosphorylation and downstream signaling. | ||||||